SNDX — Syndax Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $1.22bn
- $1.25bn
- $172.35m
Brief: Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Syndax Pharmaceuticals Q2 EPS USD -0.83
Syndax Pharmaceuticals Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: Syndax Announces FDA Priority Review Of sNDA For Revuforj In Relapsed Or Refractory mNPM1 Acute Myeloid Leukemia
Syndax Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-THOR Industries, TG Therapeutics, Target
Syndax Pharmaceuticals drops on wider quarterly loss
Syndax Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Syndax Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Incyte And Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvo™ (Axatilimab-Csfr) 9 mg And 22 mg Vial Sizes
Brief: Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Syndax Pharmaceuticals Inc - Eliminates Chief Medical Officer Position
U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart
Health Rounds: New combination treatments promising for blood cancers
Brief: Syndax Announces Additional Positive Data for Revuforj from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Brief: Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals